I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the US and China, achieving milestones as planned. The Company is progressing its US combination trial (NCT03934814), studying lemzoparlimab in combination with Rituxan® and Keytruda® in dose expansion cohorts in non-Hodgkin lymphoma (NHL) and advanced solid tumors, respectively. The combination study with Rituxan® will enroll NHL patients from both the US and China. Topline results from this study are expected next year.

I-MAB Logo (PRNewsfoto/I-Mab Biopharma)

“The results from early investigational studies support the notion that lemzoparlimab is a differentiated CD47 antibody therapy for cancers that remains among the most common causes of death around the world,” said Jordan Berlin

Read More

CdA council puzzles over piecing together mixed-use development along Spokane River

The city of Coeur d’Alene has acquired almost 5 acres of land adjacent to an ambitious, publicly owned. mixed-use development on a prime spot near downtown and on the banks of the Spokane River.

Now it has to decide what to do with it.

That decision was the subject of a lengthy presentation and discussion at Tuesday’s City Council meeting, where council members, Mayor Steve Widmyer, an engineer enlisted to help design the development and the head of the city’s urban renewal agency, ignite CDA, discussed their options.

The possibilities on the table ranged from creating a gated community on the triangular parcel to building office, hotel or apartment towers, to constructing a mix of townhomes and houses.

Council members ultimately decided to take a couple of weeks to mull over the kind of decision usually left to private developers.

As they do so, they will have to consider a

Read More

New data supports development of colchicine for the prevention of acute respiratory distress syndrome

The MarketWatch News Department was not involved in the creation of this content.

MONTREAL, Dec. 03, 2020 (GLOBE NEWSWIRE) — TheMontreal Heart Institute (MHI) has announced that colchicine, a widely available low-cost drug, reduces acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and respiratory failure in pre-clinical models1. The article reporting these results was published yesterday by the Public Library of Science ONE (PLOS ONE) 1.

“This study was designed and executed in the wake of the COVID-19 pandemic as there were no effective therapies at that time to prevent SARS-CoV-2 related lung injury and ARDS,” said Dr. Jean-Claude Tardif, Director of the MHI Research Center, Professor of Medicine at the University of Montreal, COLCORONA Principal Investigator and co-principal lead author of the study published in PLOS ONE. “In the context of COVID-19, there is an

Read More

Trump signs another executive order on governmental AI development

Outgoing US President Donald Trump on Thursday signed an executive order that aims to guide how federal agencies adopt artificial intelligence (AI) as part of efforts to build public trust in the government using this technology. 

The order itself directs federal agencies to be guided by nine principles when designing, developing, acquiring, and using AI. These principles emphasise that AI use by federal agencies be lawful; purposeful and performance-driven; accurate, reliable, and effective; safe, secure, and resilient; understandable; responsible and traceable; regularly monitored; transparent; and accountable. 

To implement these principles, the order directs the Office of Management and Budget to create a roadmap by the end of May 2021 for how the government will better support the use of AI. This roadmap will include a schedule for engaging with the public and timelines for finalising relevant policy guidance. 

The order also calls on agencies to continue to use voluntary consensus

Read More

Despite development slowdown, the state’s life science industry keeps on building

From the industry’s traditional hub in Cambridge’s Kendall Square to emerging hot spots in Fort Point and the Fenway to vast campuses in more distant locations such as the former Fort Devens, life science companies are launching a wide array of projects, fueled by investors attracted to a fast-growing industry.

“There’s just tremendous interest in investing in these sort of projects,” said John Bonnano, chief investment officer at IQHQ, a real estate firm that’s launching two major life science developments here, and earlier this month closed on a $1.7 billion fund to finance more in Boston, San Francisco, and San Diego. “There’s an awful lot of capital out there right now.”

It’s chasing a market that has only become stronger relative to other real estate sectors. Traditional office tenants now occupy about 3 million fewer square feet of space across Greater Boston than they did at the start of the

Read More

LRA’s 2020 LMTA Grantees Focus on Finding Targets for New Lupus Drug Development

NEW YORK, Dec. 3, 2020 /PRNewswire/ — The Lupus Research Alliance is proud to announce the 2020 recipients of its Lupus Mechanisms and Targets Award (LMTA). The highly competitive grant gives researchers up to $200,000 a year for up to three years. As indicated by the title of the award, the 2020 awardees are each examining different possible mechanisms that could cause or contribute to lupus and are hoping to find novel biological targets and strategies for the development of new medicines to treat the disease.

Following are summaries of each exciting project:

Marcus Clark, MD, The University of Chicago
Determining which cells cause kidney inflammation in individual lupus patients
The LMTA will allow Dr. Clark to use cutting-edge computer programs to analyze images from the kidneys of lupus patients to see which immune cells in each patient are interacting to cause inflammation. These different interactions might indicate how each

Read More

Intel, partners make new strides in Loihi neuromorphic computing chip development

Intel has released new performance benchmarks for the Loihi neuromorphic computing processor, revealing improvements in power consumption and efficiency. 

During Intel’s virtual Lab Day, on Thursday, the tech giant revealed Loihi chip improvements in voice command recognition, gesture recognition in artificial intelligence (AI) applications, image retrieval, search functions, and robotics. 

Neuromorphic computing aims to use computer science to propel rule and classical logic-based AI builds into more flexible systems that emulate human cognition, including contextual interpretation, sensory applications, and autonomous adaptation. 

Intel says that neuromorphic computing focuses on emulating the human brain and implementing stable probabilistic computing, which creates “algorithmic approaches to dealing with the uncertainty, ambiguity, and contradiction in the natural world” — just like humans are capable of.

However, speaking to attendees of the virtual event, Rich Uhlig, VP and Director of Intel Labs added a caveat: progress in neuromorphic computing has “come at the cost of ever-increasing

Read More

Norristown Calls For Development Proposals On Downtown Property

NORRISTOWN, PA — Norristown and Montgomery County officials are on the hunt for a qualified developer to give purpose to 10 contiguous tracts of undeveloped land in downtown Norristown.

The county’s redevelopment authority last month issued a request for proposal (RFP) calling on real estate developers to “acquire, design, finance, construct, manage, and market” the infill site composed of approximately 4,000 square feet.

In the RFP, the redevelopment authority said the property was held for years by a speculative owner “whose actions impeded development or acquisition.” It was only recently acquired by the county.

Now, officials hope to create a transit-oriented development to give the property meaning and add value to Norristown’s Town Center zoning district.

Municipal Administrator Crandall Jones told radio station WHYY the initiative aims to “create some additional density in the town to help diversify our tax base,” Jones said.

According to the RFP, the property is

Read More

Dashed Mill Race Inn development plans leave future of Geneva site in question

For four years, the former Mill Race Inn site in Geneva has sat empty except for the remnants of a historic stone structure protected by a tarp.

It’ll stay that way — at least for now — after the city council rejected the latest development proposal for the prime parcel of land on the Fox River at Geneva’s eastern gateway.



At a meeting Monday, Geneva’s 10 aldermen voted unanimously to reject the proposal presented by the Shodeen Family Foundation, signaling the end of a $38 million project introduced nearly 18 months ago.

The proposed project called for 116 rental apartments, eight townhouses, 2,000 square feet of commercial space, 155 covered parking spaces, deconstruction and reinterpretation of the original historic structure to adhere to its landmark status, and riverfront amenities.

The decision will cost the city $273,000 — to come from tax increment financing funds — to cover all the expenses

Read More